HLA-A2 restraint tumor antigen peptide originating in SART-1
AssigneesKyogo Itoh, Sumitomo Pharmaceuticals Company, Limited
InventorsKyogo Itoh, Terutada Kobayashi
Life of this patent
Estimating the term…
Abstract
An HLA-A2 restricted tumor antigen peptide originated fromr SART-1, derivatives thereof having characteristics functionally equivalent thereto; therapeutic, prophylactic or diagnostic agents for tumors which utilize the tumor antigen peptide or its derivative, a recombinant DNA, recombinant polypeptide or antibody related to said tumor antigen peptide, or use thereof; an antigen presenting cell presenting the said tumor antigen peptide or use thereof; cytotoxic T lymphocyte specific for said tumor antigen peptide or use thereof.
Claims7
A tumor antigen peptide consisting of 8-11 amino acid residues, which has an amino acid sequence selected from those each comprising the entire or a partial amino acid sequence(s) of that shown in any one of SEQ ID NO:
- 1 to SEQ ID NO:
- 34 and which binds to HLA-A2 antigen and is recognized by cytotoxic T lymphocytes.
A tumor antigen peptide derivative consisting of 8-11 amino acid residues, which has an amino acid sequence selected from those each comprising the entire or a partial amino acid sequence(s) of a sequence wherein the amino acid residue at position 2 and/or C-terminus of the sequence shown in any one of SEQ ID NO:
- 1 to SEQ ID NO:
- 34 is replaced by different amino acid, and which binds to HLA-A2 antigen and is recognized by cytotoxic T lymphocytes.
Dependencies are inferred from the claim text.